print_label | resize_label

FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

SWEET REDUCTIONS

REDUCE A1C, WITH ADDITIONAL WEIGHT* AND SBP BENEFITS

REDUCE A1C, WITH ADDITIONAL WEIGHT* AND SBP BENEFITS

FARXIGA is not indicated for weight loss or the treatment of hypertension.

*Up to 7-lb. weight reduction was reported in clinical trials.

*Up to 7-lb. weight reduction was reported in clinical trials.

SBP reductions when added to metformin.

SBP reductions when added to metformin.

Approximately 70 g/day at 12 weeks

In a pharmacodynamic study, use of FARXIGA resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12. Results may vary.